Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INIPARIB+ irinotecan · 1 trial · 4 indications
AS measured by intra or extra cranial time to progression (TTP)
| Arm | Type | Description |
|---|---|---|
| INIPARIB, irinotecan | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| INIPARIB + irinotecan | DRUG | 21 day cycle |
Inclusion Criteria - 1. Histologically-confirmed, ER negative, PR negative and Her2 negative adenocarcinoma of the breast with brain lesion on radiographic imaging. 2. ECOG Performance Status of 0-2. 3. Life expectancy of \>12 weeks. 4. No limit to prior therapies with last anti-cancer treatment ≥ ...
INIPARIB+ irinotecan is an investigational oncology combination being studied for advanced solid tumors, breast cancer in females, malignant neoplasms, and primary peritoneal cancer. It is a small molecule therapeutic developed by Sanofi. The drug is currently in clinical development and has not been approved by regulatory authorities.
INIPARIB is a PARP inhibitor, and when combined with irinotecan, a topoisomerase I inhibitor, the combination targets DNA repair pathways in cancer cells. This mechanism is being evaluated in clinical trials for various solid tumors and breast cancers. The combination is designed to exploit vulnerabilities in tumor cells' DNA damage response.
INIPARIB+ irinotecan is developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of this combination therapy in oncology indications.
INIPARIB+ irinotecan is in Phase 2 clinical development. The drug is investigational and has not received FDA approval. Sanofi has completed two trials for this combination, with a total enrollment of 642 patients across studies in advanced solid tumors and breast cancer.
INIPARIB+ irinotecan has been studied in two completed trials: NCT00540358, a Phase 2 study in triple negative metastatic breast cancer, and NCT00938652, a Phase 3 study of gemcitabine/carboplatin with or without BSI-201 in metastatic breast cancer. Both trials enrolled female patients in the United States.
Yes, INIPARIB is also known as BSI-201, as referenced in clinical trial titles. The combination INIPARIB+ irinotecan is being studied in oncology indications. Sanofi has conducted trials using the BSI-201 designation for this PARP inhibitor in breast cancer and advanced solid tumors.